Theresa Matkovits
2021
In 2021, Theresa Matkovits earned a total compensation of $1.3M as Chief Development Officer at Matinas BioPharma Holdings, a 7% increase compared to previous year.
Compensation breakdown
| Bonus | $147,000 |
|---|---|
| Option Awards | $812,636 |
| Salary | $378,525 |
| Total | $1,338,161 |
Matkovits received $812.6K in option awards, accounting for 61% of the total pay in 2021.
Matkovits also received $147K in bonus and $378.5K in salary.
Rankings
In 2021, Theresa Matkovits' compensation ranked 7,710th out of 12,405 executives tracked by ExecPay. In other words, Matkovits earned more than 37.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,710 out of 12,405 | 38th |
Division Manufacturing | 3,399 out of 5,494 | 38th |
Major group Chemicals And Allied Products | 1,508 out of 2,369 | 36th |
Industry group Drugs | 1,342 out of 2,090 | 36th |
Industry Pharmaceutical Preparations | 989 out of 1,537 | 36th |
Source: SEC filing on September 22, 2022.
Matkovits' colleagues
We found two more compensation records of executives who worked with Theresa Matkovits at Matinas BioPharma Holdings in 2021.
News
Matinas BioPharma Holdings CEO Jerome Jabbour's 2022 pay falls 55% to $1.7M
September 19, 2023
Matinas BioPharma Holdings CEO Jerome Jabbour's 2021 pay jumps 26% to $3.7M
September 22, 2022
Matinas BioPharma Holdings CEO Jerome Jabbour's 2019 pay rises 6% to $1.3M
October 1, 2020
Matinas BioPharma Holdings CEO Jerome Jabbour's 2018 pay slips 1% to $1.3M
September 24, 2019